Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 4
Submit an article Journal homepage
537
Views
6
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma

Stefano LuminariDepartment of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy; Correspondence[email protected]
,
Maria GoldanigaFondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy;
,
Marina CesarettiDepartment of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy;
,
Lorella OrsucciHematology, Città della Salute e della Scienza, Torino, Italy;
,
Alessandra TucciDivision of Hematology, Spedali Civili, Brescia, Italy;
,
Alessandro PulsoniDivision of Hematology, Sapienza University, Roma, Italy;
,
Flavia SalviAzienda ospedaliera nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria;
,
Luca ArcainiDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;
,
Angelo Michele CarellaAzienda Ospedaliera Universitaria ‘San Martino’, Genova, Italy;
,
Alessandra TedeschiAzienda Ospedaliera Ospedale Niguarda Ca’ Granda, Milano, Italy;
,
Antonello PintoUOSC di Ematologia Oncologica, Istituto Nazionale Tumori, Fondazione Pascale, IRCCS, Napoli, Italy;
,
Caterina StelitanoAzienda ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
&
Luca BaldiniFondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy;
show all
Pages 880-887 | Received 18 May 2015, Accepted 29 Aug 2015, Published online: 08 Feb 2016

References

  • Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
  • Ben-Ezra J, Burke JS, Swartz WG, et al. Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood. 1989;73:579–587.
  • Coiffier B, Thieblemont C, Felman P, et al. Indolent non follicular lymphomas: characteristics, treatment, and outcome. Semin Hematol. 1999;36:198–208.
  • Landgren O, Tilly H. Epidemiology, pathology and treatment of non-follicular indolent lymphomas. Leuk Lymphoma. 2008;49(Suppl. 1):35–42.
  • Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, et al. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol. 1999;36:104–114.
  • Papamichael D, Norton AJ, Foran JM, et al. Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972 to 1996. J Clin Oncol. 1999;17:2847–2853.
  • Seng JE, Peterson BA. Indolent B-cell non-Hodgkin's lymphomas. Oncology (Williston Park). 1997;11:1883–1894.
  • Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: recent advances in biology and therapy. Clin Adv Hematol Oncol. 2009;7:677–690.
  • Treon SP. How I treat Waldenstrom macroglobulinemia. Blood. 2009;114:2375–2385.
  • Zinzani PL. Traditional treatment approaches in B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44(Suppl. 4):S6–14.
  • Baldini L, Brugiatelli M, Luminari S, et al. Treatment of indolent B-Cell non follicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol. 2003;21:1459–1465.
  • Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-Cell non follicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer. 2012;118:3954–3961.
  • Ferrario A, Merli F, Luminari S, et al. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Ann Hematol. 2011;90:323–330.
  • Rummel MJ, Niederle N, Maschmeyer G, et al; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as fi rst-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
  • Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944–2952.
  • Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol. 1987;14:65–74.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin’s Lymphoma. J Clin Oncol. 2005;23:3383–3389.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
  • Sacchi S, Marcheselli L, Bari A, et al. Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study. Haematologica. 2008;93:398–404.
  • Waterman J, Rybicki L, Bolwell B, et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47:488–493.
  • Salar A, Domingo-Domenech E, Panizo C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1:e104–e111.
  • Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) shows superior efficacy in comparison to Bendamustine (B) and Rituximab (BR) in previously untreated and physically fit patients (pts) with advanced Chronic Lymphocytic Leukemia (CLL): final analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (Suppl).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.